Filtered By:
Drug: Zivast
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 875 results found since Jan 2013.
Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery
Aim: Atherosclerosis is the underlying reason for nearly all causes of coronary artery disease and peripheral arterial disease and many cases of stroke. Carotid color-Doppler ultrasonography is a popular tool for evaluating atherosclerosis of the carotid artery. The aim of this study was to generate a rabbit model of carotid arterial atherosclerotic stenosis and the subsequent investigating the effect of high-dose atorvastatin therapy on color-Doppler ultrasonography parameters in this model.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Hossein Mehrad, Manijhe Mokhtari-Dizaji, Hossein Ghanaati Source Type: research
Specific rescue by ortho ‐hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - September 7, 2017 Category: Neurology Authors: Ver ónica Guirao, Octavi Martí‐Sistac, Nuria DeGregorio‐Rocasolano, Jovita Ponce, Antoni Dávalos, Teresa Gasull Tags: Original Article Source Type: research
Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin
.
Source: Nutritional Neuroscience - September 26, 2017 Category: Nutrition Authors: Sanaz Nasoohi Leila Simani Fariba Khodagholi Sara Nikseresht Mehrdad Faizi Nima Naderi Source Type: research
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264.
PMID: 28974520 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2017 Category: Cardiology Authors: Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P Tags: Circulation Source Type: research
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes, and the response to atorvastatin and EZE combination was similar for both men and women.
PMID: 28553847 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 6, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research
Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research
This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often.
Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago.
“It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.
Conclusions -The present post-hoc analysis from TNT shows that increased TRL-C levels associate an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid-lowering with statins among CHD patients with high TRL-C. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00327691.
PMID: 29618599 [PubMed - as supplied by publisher]
Source: Circulation - April 4, 2018 Category: Cardiology Authors: Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK Tags: Circulation Source Type: research
Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish.
Abstract
Impaired vascular integrity leads to serious cerebral vascular diseases such as intracerebral hemorrhage (ICH). In addition, high-dose statin therapy is suggested to cause increased ICH risk due to unclear effects of general inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) on the vascular system. Here we evaluated the protective effects of sodium tanshinone IIA sulfonate (STS), which has high efficacy and safety in clinical studies of ischemic stroke, by using atorvastatin (Ator) induced ICH zebrafish embryos and human umbilical vein endothelial cells (HUVECs). By using double transgenic Tg(...
Source: Toxicology and Applied Pharmacology - May 3, 2018 Category: Toxicology Authors: Zhou ZY, Huang B, Li S, Huang XH, Tang JY, Kwan YW, Hoi PM, Lee SM Tags: Toxicol Appl Pharmacol Source Type: research
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - June 13, 2018 Category: Internal Medicine Source Type: research
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
ConclusionsAmong clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment.Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.ResumenIntroducción y objetivosLa vigente guía de práctica clínica para el tratamiento de la hipercolesterolemia recomienda mantener la terapia intensiva con estatinas de los pacientes tratados con implante de stent farmacoactivo (SFA). Sin embargo, el tratamiento intensivo con estatinas, una vez estabilizado el paciente, con fre...
Source: Revista Espanola de Cardiologia - July 5, 2018 Category: Cardiology Source Type: research
Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin
.
Source: Nutritional Neuroscience - September 26, 2017 Category: Nutrition Authors: Sanaz Nasoohi Leila Simani Fariba Khodagholi Sara Nikseresht Mehrdad Faizi Nima Naderi Source Type: research
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
ConclusionsAmong clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment.Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.ResumenIntroducción y objetivosLa vigente guía de práctica clínica para el tratamiento de la hipercolesterolemia recomienda mantener la terapia intensiva con estatinas de los pacientes tratados con implante de stent farmacoactivo (SFA). Sin embargo, el tratamiento intensivo con estatinas, una vez estabilizado el paciente, con fre...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research
Fractal dimension based carotid plaque characterization from three-dimensional ultrasound images
AbstractIrregularity of the plaque surface associated with previous plaque rupture plays an important role in the risk estimation of stroke caused by carotid atherosclerotic lesions. Thus, the aim of this study is to develop and validate novel vulnerability biomarkers from three-dimensional ultrasound (3DUS) images by analyzing the surface morphological characteristics of carotid plaque using fractal geometry features. In the experiments, a total of 38 3DUS plaque images were obtained from two groups of patients treated with 80 mg of atorvastatin or placebo daily for 3 months respectively. Two types of 3D fractal dimens...
Source: Medical and Biological Engineering and Computing - July 26, 2018 Category: Biomedical Engineering Source Type: research
Atorvastatin Pretreatment Attenuates Ischemic Brain Edema by Suppressing Aquaporin 4
Background: Cerebral edema, a serious complication of acute cerebral infarction, has a crucial impact on morbidity and mortality in the early stage of cerebral infarction. And aquaporin 4 (AQP4), a bidirectional water transporting protein, plays a pivotal role in edema formation. At experimental model, it has proven that atorvastatin could exert pleiotropic neuroprotection on acute cerebral infarction independent of its cholesterol-lowering action. It was a common protective manifestation that atorvastatin can reduce the infarct volume and cerebral edema.
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Zhi-Juan Cheng, Ting-Min Dai, Yao-Yao Shen, Jian-Le He, Juan Li, Jiang-Long Tu Source Type: research
